Metropolitan Life Insurance Co. NY decreased its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 2.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,202 shares of the biopharmaceutical company’s stock after selling 922 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Lexicon Pharmaceuticals were worth $476,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. FMR LLC raised its stake in shares of Lexicon Pharmaceuticals by 0.3% in the first quarter. FMR LLC now owns 15,647,859 shares of the biopharmaceutical company’s stock worth $224,390,000 after buying an additional 42,408 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Lexicon Pharmaceuticals by 16.3% in the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock worth $59,773,000 after buying an additional 585,222 shares in the last quarter. Kingdon Capital Management L.L.C. raised its stake in shares of Lexicon Pharmaceuticals by 11.4% in the first quarter. Kingdon Capital Management L.L.C. now owns 1,690,273 shares of the biopharmaceutical company’s stock worth $24,239,000 after buying an additional 172,698 shares in the last quarter. State Street Corp raised its stake in shares of Lexicon Pharmaceuticals by 3.1% in the first quarter. State Street Corp now owns 1,641,167 shares of the biopharmaceutical company’s stock worth $23,536,000 after buying an additional 49,802 shares in the last quarter. Finally, Loomis Sayles & Co. L P raised its stake in shares of Lexicon Pharmaceuticals by 9.0% in the first quarter. Loomis Sayles & Co. L P now owns 913,833 shares of the biopharmaceutical company’s stock worth $13,104,000 after buying an additional 75,461 shares in the last quarter.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) traded up 0.76% during mid-day trading on Friday, reaching $14.62. 630,283 shares of the company were exchanged. Lexicon Pharmaceuticals, Inc. has a 1-year low of $13.41 and a 1-year high of $19.62. The stock’s market capitalization is $1.54 billion. The stock’s 50-day moving average price is $16.17 and its 200-day moving average price is $15.41.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The company had revenue of $12 million during the quarter, compared to analysts’ expectations of $18.34 million. During the same period last year, the business posted ($0.37) EPS. Lexicon Pharmaceuticals’s revenue for the quarter was down 40.3% on a year-over-year basis. On average, equities research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post ($1.45) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/13/lexicon-pharmaceuticals-inc-lxrx-position-lowered-by-metropolitan-life-insurance-co-ny.html.

A number of analysts have recently issued reports on LXRX shares. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Wedbush reissued an “ourperform” rating and set a $39.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, August 7th. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Finally, ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $27.00.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Stock Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.